Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts by Brinkmann, Hannah et al.
Histone Hyperacetylation Induced by Histone Deacetylase
Inhibitors Is Not Sufficient to Cause Growth Inhibition in Human
Dermal Fibroblasts*
Received for publication, January 10, 2001, and in revised form, March 23, 2001
Published, JBC Papers in Press, April 13, 2001, DOI 10.1074/jbc.M100206200
Hannah Brinkmann‡, Alison L. Dahler‡, Claudia Popa‡§, Magdalena M. Serewko‡¶,
Peter G. Parsonsi, Brian G. Gabrielli**, Andrew J. Burgess**, and Nicholas A. Saunders‡ ‡‡ §§
From the ‡Epithelial Pathobiology Group, Centre For Immunology and Cancer Research, University of Queensland
Department of Medicine, Princess Alexandra Hospital, Brisbane, Queensland 4102, the iCancer Unit, Queensland Institute
of Medical Research, Herston, Queensland 4006, the **Department of Pathology, University of Queensland, Medical
School, Herston, Queensland 4006, and the ‡‡Department of Physiology and Pharmacology, University of Queensland, St.
Lucia, Queensland 4067, Australia
Use of specific histone deacetylase inhibitors has re-
vealed critical roles for the histone deacetylases (HDAC)
in controlling proliferation. Although many studies
have correlated the function of HDAC inhibitors with
the hyperacetylation of histones, few studies have spe-
cifically addressed whether the accumulation of acety-
lated histones, caused by HDAC inhibitor treatment, is
responsible for growth inhibition. In the present study
we show that HDAC inhibitors cause growth inhibition
in normal and transformed keratinocytes but not in nor-
mal dermal fibroblasts. This was despite the observation
that the HDAC inhibitor, suberic bishydroxamate
(SBHA), caused a kinetically similar accumulation of
hyperacetylated histones. This cell type-specific re-
sponse to SBHA was not due to the inactivation of SBHA
by fibroblasts, nor was it due to differences in the ex-
pression of specific HDAC family members. Remarkably,
overexpression of HDACs 1, 4, and 6 in normal human
fibroblasts resulted in cells that could be growth-inhib-
ited by SBHA. These data suggest that, although histone
acetylation is a major target for HDAC inhibitors, the
accumulation of hyperacetylated histones is not suffi-
cient to cause growth inhibition in all cell types. This
suggests that growth inhibition, caused by HDAC inhib-
itors, may be the culmination of histone hyperacetyla-
tion acting in concert with other growth regulatory
pathways.
Analysis of histone-modifying enzymes such as the histone
acetyltransferases (HATs)1 and deacetylases has resulted in
significant advances in our understanding of transcriptional
regulation (1–4). These studies have resulted in a model of
transcription in which transcriptionally competent genes are
transcribed or repressed dependent upon their ability to recruit
either HATs or histone deacetylases to the promoter (4). In
these models, recruited histone acetyltransferases associate
with transcription factor complexes (5–8), resulting in the
acetylation of nucleosomal histones, relaxation of nucleosomal
integrity, and hence transcription. Conversely, transcriptional
repression occurs when histone deacetylases (and cofactors) are
recruited to DNA-bound transcription factors, resulting in the
removal of acetyl groups from NH2-terminal lysines causing a
“tightening” of nucleosomal integrity and a suppression of tran-
scription (9–13).
The isolation and synthesis of new and potent inhibitors of
histone deacetylase enzymes (HDACs) has allowed us to iden-
tify some of the biological outcomes resulting from manipula-
tion of histone deacetylase activity. For example, it is now
established that treatment of cells in vitro and in vivo with
HDAC inhibitors can result in specific functional outcomes
such as cell cycle arrest (14–16), apoptosis/cell death (17–19),
or differentiation (19–21). These outcomes to a large extent are
cell type-specific and have raised the potential that the HDAC
inhibitors may represent a new and important class of antican-
cer therapeutic agents (4).
HDAC inhibitors comprise a diverse range of unrelated com-
pounds that all induce an accumulation of hyperacetylated
histones (21). The biological effects of these compounds (e.g. cell
cycle arrest, cell death, or differentiation) are thought to result
from the accumulation of acetylated histones and transcrip-
tional activation that results from the use of these compounds.
For instance, sodium butyrate (NaB), suberic bishydroxamate
(SBHA), and trichostatin A (TSA) are all HDAC inhibitors that
induce an accumulation of acetylated histone H4 (21, 22).
These agents are also able to induce growth inhibition, which
has been shown to be associated causally with an induction of
the cyclin-dependent kinase inhibitor p21 in colon carcinoma
cells (15).
Although the data for the colon carcinoma cells used in the
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p21 studies appear compelling, there are several pieces of evi-
dence that suggest that the biological outcomes, in response to
the HDAC inhibitors in other cell types, may not be explained
simply by an accumulation of acetylated histones. For instance,
1) it has been shown that certain cell types (human dermal
fibroblasts or murine erythroleukemia cells) are able to grow in
the presence of HDAC inhibitors and in the presence of hyper-
acetylated histones (6, 18, 22). 2) We have shown previously
that the accumulation of acetylated histone H4 in response to
NaB or TSA in keratinocytes and the squamous cell carcinoma
cell line, SCC25, is transient and is temporally uncoupled from
the process of growth inhibition (21). 3) Recently it has been
suggested that the cell cycle regulator, Rb, mediates its growth
inhibitory effects by associating with an HDAC and thus sup-
pressing E2F activity (23–25). Although this has been convinc-
ingly shown in vitro, it should be noted that the E2F activation
caused by HDAC inhibitors (23–25) is inconsistent with the
growth inhibition observed in cells following HDAC inhibitor
treatment. 4) Recent studies have shown that nonhistone pro-
teins such as E2F1 (26) and p53 (27, 28) are subject to both
acetylation and deacetylation, and more importantly these
modifications result in alterations in functional activity of
these important transcriptional controllers of growth and differ-
entiation. 5) HDAC inhibitors do not lead to global deregulation
of transcription (29). These observations raise the possibility that
biological effects of HDAC inhibitors may be, in part, mediated by
events independent of the acetylation of histones (30).
In the present study we wished to examine the relationship
between the accumulation of acetylated histones in response to
HDAC inhibitors and the induction of growth arrest in kerati-
nocytes, fibroblasts, and SCC25 cells. We report that the in-
duction of acetylated histones in fibroblasts is not associated
with growth inhibition. Our data are consistent with a model in
which growth inhibition in response to HDAC inhibitors is cell
type-specific and dictated by the activity of pre-existing regu-
latory pathways in the cells.
MATERIALS AND METHODS
Cells, Tissue Culture, and Reagents—Human epidermal keratino-
cytes (HEKs) were isolated from neonatal foreskins following circumci-
sion and cultured in keratinocyte serum-free medium (Life Technolo-
gies Inc, Sydney, New South Wales (NSW), Australia) as described (31).
Human dermal fibroblasts (HDFs) were also isolated from foreskin
samples following circumcision and were cultured in Dulbecco’s modi-
fied Eagle’s medium as described (32). The keratinocyte-derived squa-
mous cell carcinoma cell line, SCC25, was obtained from the American
Type Tissue Culture Collection and cultured as described (31). All cells
in this study were used under subconfluent, proliferative conditions.
The histone deacetylase inhibitors sodium butyrate (NaB), the R (R-PB)
and S (S-PB) enantiomeric forms of phenylbutyrate, and the hybrid
polar compound hexamethylene bisacetamide (HMBA) were purchased
from Sigma (Sydney, NSW, Australia). The synthesis of azelaic-1-hy-
droxyamate-9-anilide (AAHA) has been described previously (18) as has
the synthesis of suberic bishydroxamate (SBHA, Ref. 33).
Plasmids, Transfections, and Cell Line Selection—Human histone
deacetylase 1 (HDAC1; Ref. 34) and histone deacetylases 4, 5, and 6
(HDACs 4–6; Ref. 35) in the pBJ5 expression plasmid were a generous
gift from Prof. Schreiber (Harvard University, Cambridge, MA). A glu-
tathione S-transferase-tagged murine HDAC2 plasmid (36) and a hu-
man HDAC3 expression plasmid (in the pGEX expression plasmid; Ref.
37) were a generous gift from Prof. Seto (H. Lee Moffitt Cancer Center
and Research Institute, University of San Francisco, San Francisco,
CA). To establish stably expressing HDF cell lines, 75-cm2 flasks of
passage 2 HDFs (50% confluent) were transfected with 9 mg of HDAC
expression vector 1 3 mg of the pSV2neo neomycin expression vector
followed by selection with 500 mg/ml G418 (31). Transfection used a
similar protocol to that described for keratinocytes (38) in the presence
of LipofectAMINE Plus reagent as per manufacturer’s instructions
(Life Technologies, Inc.).
Apoptosis Assay—Estimates of apoptosis induced by NaB (3 mM),
AAHA (3 mM), or SBHA (100 mM) were determined following a 24-h
treatment with the compounds. Apoptosis was estimated using the
TUNEL assay as per the manufacturer’s protocol (Roche, Brisbane,
Queensland (QLD), Australia). Briefly, cells were cultured in 25-cm2
flasks, trypsinized, and then subjected to cytospinning (100 3 g for 2
min) before being used in the TUNEL assay. An apoptotic index was
then derived (apoptotic cells/total cells * 100/1).
Western Blotting and Histone Isolation—Protein expression and hi-
stone acetylation status were determined by immunoblotting. For Rb,
p21, acetyllysine, or FLAG-tagged HDAC protein analysis, cells were
trypsinized and rinsed with phosphate-buffered saline (137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4). An aliquot was
removed for protein determination, and the remaining protein solubi-
lized in 23 sample buffer (25 mM Tris-Cl, 5% glycerol, 5% SDS, 5%
b-mercaptoethanol, 0.005% bromphenol blue) and boiled for 5 min.
Twentyfive micrograms of protein were then run on a 7.5% SDS-PAGE
gel (16 cm 3 18 cm), transferred to polyvinylidene difluoride membrane,
and probed with antibodies specific for Rb (sc-50; 1:1000), p107 (sc-318;
1:1000), p130 (sc-317; 1:1000), p21 (sc-397; 1:1000; Santa Cruz Biotech-
nology, Brisbane, QLD, Australia), acetyllysine (06-933; 1:1000; Up-
state Biotechnology, Parkville, Victoria, Australia), or anti-FLAG anti-
body (1 mg/ml; F-3165; Sigma, Sydney, NSW, Australia). To determine
histone acetylation status, cells were harvested by trypsinization and
histones isolated as described (21). Five micrograms of purified histones
were then run on a 15% SDS-PAGE gel and blotted to PVDF membrane
and probed with either an antibody specific for acetylated histone H4
(06-598) or an antibody specific for acetylated lysines (06-933; Upstate
Biotechnology Inc, Melbourne, Victoria, Australia). Purified H2A, H3,
and H4 (Roche) were run in separate lanes to confirm the identity of the
purified histones. All immunoblots were visualized using a primary
antibody dilution of 1:1000 and chemiluminescent detection (ECL; Am-
ersham, Sydney, NSW, Australia) as described (21). Quantitation of
acetylation level was determined by densitometric analysis of the au-
toradiographs as described (21).
RNA Isolation and Northern Blotting—Total cellular RNA was iso-
lated from cells following disruption in Trizol (Life Technologies, Inc.)
using previously described protocols (38, 39). Enrichment for poly(A)1
RNA by oligo(dT)-cellulose (Collaborative Research Inc., Bedford, MA)
chromatography was then performed as described (40). One microgram
of poly(A)1 RNA (HEKs and HDFs) was then electrophoresed, trans-
ferred to nylon membrane (Hybond N; Amersham Pharmacia Biotech),
and hybridized with probes specific for HDACs 1–6 and actin. Probes
for specific HDACs were made from restriction digests of the expression
plasmids using the following restriction enzymes; HDAC1 5 NotI/
EcoRI, HDAC2 5 XhoI, HDAC3 5 EcoRI, HDAC4 5SalI/SacI,
HDAC5 5 SacI/SacII, HDAC6 5 SphI/AvrII. All inserts were gel-
purified. Probe labeling with [32P]dCTP (Geneworks, Adelaide, South
Australia, Australia), hybridizing, and washing were performed as de-
scribed previously (41). A probe against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used to normalize for loading inequalities
and has been described previously (42). All blots were visualized by
autoradiography with Kodak XAR5 film. Images were then captured
using a laser densitometer (Molecular Dynamics, Sydney, NSW, Aus-
tralia) and imported into Adobe Photoshop.
Proliferation Assay and Cell Cycle Analysis—Proliferation was meas-
ured directly either by assaying for [3H]thymidine incorporation (43) or
by an analysis of the cell cycle in propidium iodide-stained cells as
described (44).
Kinetic Analysis and Statistics—Dose response analysis for prolifer-
ation suppression by histone deacetylase inhibitors was estimated by
nonlinear regression analysis with the following equation P 5 P0e
2k[I],
where P 5 DNA synthesis, P0 5 DNA synthesis in the absence of
inhibitor, k 5 rate constant defining the inhibition DNA synthesis, and
[I] 5 the concentration of HDAC inhibitor (39). Dose-response analysis
for the accumulation of acetylated histones was estimated by nonlinear
regression analysis using the following equation: Ac 5 (Acmax * EC50)/
(EC50 1 [I]) where Ac 5 the acetylation level, Acmax 5 the maximal
amount of histone acetylation, EC50 5 the concentration at which
acetylation is half-maximal and [I] 5 the concentration of HDAC inhib-
itor. All data were fitted using GraphPad Prism software (Brisbane,
QLD, Australia).
RESULTS
Growth Inhibition by Histone Deacetylase Inhibitors Is Cell-
selective—We have shown previously that the histone deacety-
lase inhibitors NaB and TSA are able to inhibit DNA synthesis
in keratinocytes and a number of keratinocyte-derived squa-
mous cell carcinoma cell lines (21). Treatment of keratinocytes
and SCC25 cells with varying concentrations of NaB, R-PB,
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S-PB, AAHA, SBHA, or the hybrid polar compound, HMBA,
indicated that only NaB, AAHA, and SBHA induced growth
inhibition (Table I). Dose-response analysis indicated that NaB
and AAHA were slightly more potent at inducing growth arrest
in keratinocytes than in SCC25 cells (Table I). In contrast, the
EC50 value for the inhibition of DNA synthesis by SBHA in
HEKs and SCC25 cells was similar (Table I). A dose-response
profile for the inhibition of DNA synthesis by R-PB or S-PB in
HEKs and SCC25 cells was not possible despite analysis out to
6 mM. A modest inhibition of DNA synthesis with R-PB and
S-PB was noted only at the 6 mM concentration in HEKs (R-PB,
40 6 13%; and S-PB, 53 6 24% that of untreated controls) and
SCC25 cells (R-PB, 112 6 14%; and S-PB, 122 6 6% that of
untreated controls). In contrast, these agents were not able to
inhibit DNA synthesis in HDFs (Table II). In fact, NaB and
AAHA, at high concentration, significantly increased DNA syn-
thesis in the HDFs (Table II). However, growth inhibition of
HDFs can eventually be induced by prolonged exposure (48 h)
to high concentrations of SBHA (300 mM). Furthermore, the
insensitivity of HDFs to SBHA could be altered by changing
media composition (data not shown). Combined, these data
clearly show that keratinocytes and the keratinocyte-derived
carcinoma cell line are sensitive to the growth inhibitory prop-
erties of histone deacetylase inhibitors whereas fibroblasts re-
main insensitive under similar conditions.
Cell cycle analysis of keratinocytes treated with varying
concentrations of SBHA for 24 h indicated that the decrease in
DNA synthesis observed in these cells (Table I) was associated
with an accumulation in G0/G1 phase (Table III). Consistent
with the results of the DNA synthesis assay in HDFs, the cell
cycle analysis did not reveal any specific blockade of the cell
cycle (Table III). There was a decrease in the percentage of
HDFs in G2/M phase following treatment with 100 mM SBHA,
which suggests that SBHA may reduce transit time through
G2/M phase and may be consistent with the modest increase in
DNA synthesis observed in HDFs following SBHA treatment
(Table II). Interestingly, the cell cycle profile observed in
SCC25 cells treated with 100 mM SBHA showed an accumula-
tion in the G2/M phase with a lesser, if any, accumulation of
cells in G0/G1 (Table III). This contrasts with the findings
observed in HEKs and suggests that different mechanisms of
action may be invoked by SBHA treatment of keratinocytes and
transformed keratinocytes. It should be noted that, following
treatment with SBHA, ;30–50% of SCC25 became detached,
which is consistent with cell death. A similar result has been
described previously for these cells (44). Thus, the findings in
the SCC25 cells most likely represent a combination of a G2/M
accumulation of SBHA-treated cells and the induction of cell
death.
A well characterized target of HDAC inhibitor action is the
induction of p21 (15) and/or the accumulation of hypophospho-
rylated Rb (16), both of which are thought to be mediated by
alterations in transcriptional control mediated by HDACs (45–
47). Following a 24-h treatment of HEKs, HDFs, and SCC25
cells with SBHA (100 mM), there was an induction of p21 pro-
tein expression in all the cell types (Fig. 1). However, the
induction of p21 was associated with a corresponding alteration
in the phosphorylation status of the pocket proteins Rb or p107
only in keratinocytes but not in HDFs or growth-inhibited
SCC25 cells (Fig. 1). Moreover, significant levels of expression
of the pocket protein p130 were observed only in keratinocytes
but were not altered by SBHA treatment (Fig. 1). The lack of an
association between SBHA-induced growth inhibition and the
phosphorylation status of Rb and p107 in SCC25 cells suggests
that a mechanism distinct from E2F suppression may be in-
volved in SBHA-induced growth suppression in SCC25 cells.
These findings are consistent with the cell cycle analysis (Table
III), which indicated that SBHA selectively induced an accu-
mulation of SCC25 cells in the G2/M phase and selectively
induced an accumulation of keratinocytes in the G0/G1 phase.
Combined, these data show that the ability of SBHA to induce
TABLE I
IC50 values for various histone deacetylase inhibitors for the inhibition
of growth in keratinocytes or SCC25 cells
Proliferating keratinocytes (HEK) or squamous cell carcinoma cells
(SCC25) were treated with varying concentrations of the indicated
compounds for 24 h. In the final 3 h of treatment, cells were co-
incubated with 2.5 mCi/ml [3H]methyl thymidine. DNA synthesis was
then estimated and the IC50 determined by nonlinear least squares
regression analysis. Data are presented as the IC50 value 6 standard
error of the estimate.
HEK SCC25
NaB 0.26 6 0.11 mM 1.28 6 0.24 mM
R-PB
S-PB
AAHA 0.68 6 0.21 mM 3.9 6 3.8 mM
SBHA 11.7 6 8.46 mM 5.39 6 5.6 mM
HMBA
TABLE II
Ability of the histone deacetylase inhibitors to inhibit DNA synthesis
in keratinocytes and fibroblasts
Proliferating keratinocytes (HEK) or human dermal fibroblasts
(HDF) were treated with maximal concentrations of the indicated com-
pounds for 24 h. In the final 3 h of treatment, cells were co-incubated
with 2.5 mCi/ml [3H]methyl thymidine. DNA synthesis was then esti-
mated and the inhibition of DNA synthesis expressed as a percentage of
the value obtained in the untreated cells. The data is presented as
mean 6 S.E. of triplicate determinations from two independent exper-
iments. * Denotes significant difference (p , 0.05) determined by Stu-
dent’s t test.
HEK HDF
Untreated 100 6 3.5 100 6 5
NaB (3 mM) 1 6 0.2* 186 6 27*
R-PB (6 mM) 40 6 13* 171 6 47
S-PB (6 mM) 53 6 24 94 6 23
AAHA (3 mM) 1.5 6 0.4* 151 6 13*
SBHA (100 mM) 1.2 6 0.3* 164 6 43
HMBA (1 mM) 202 6 79 93 6 20
TABLE III
Cell cycle analysis on human dermal fibroblasts, SCC25 cells, and
human epidermal keratinocytes treated with varying concentrations of
SBHA
Proliferating cells were treated with varying concentrations of SBHA
for 24 h. Cells were then trypsinized and stored in 70% ethanol at
220 °C until used for cell cycle analysis. Data are presented as percent-
age of total cells present in the different cell cycle phases.
[SBHA] G0/G1 S G2/M
Human dermal fibroblasts
0 mM 49.9% 20.9% 29.2%
1 mM 49.0% 23.3% 27.7%
3 mM 47.6% 22.3% 30.1%
10 mM 45.7% 24.2% 30.0%
30 mM 53.3% 20.2% 26.4%
100 mM 56.6% 24.1% 19.3%
Human epidermal keratinocytes
0 mM 60.5% 21.9% 17.6%
1 mM 56.1% 29.6% 14.3%
3 mM 57.1% 27.8% 15.1%
10 mM 64.0% 16.1% 20.0%
30 mM 64.6% 14.5% 20.9%
100 mM 71.4% 7.2% 21.4%
SCC25 cells
0 mM 44.0% 43.5% 12.5%
1 mM 41.6% 43.8% 14.6%
3 mM 42.6% 41.2% 16.2%
10 mM 40.5% 45.1% 14.3%
30 mM 40.0% 43.1% 16.9%
100 mM 45.5% 32.5% 22.0%
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growth inhibition may be mediated by events in G0/G1 or G2/M
dependent upon the cell type or transformation status.
An alternative explanation for the decrease in DNA synthe-
sis induced by HDAC inhibitors in keratinocytes and SCC25
cells may be attributable to apoptosis. Previously, agents such
as NaB or TSA have been reported to induce apoptosis in colon
carcinoma cell lines (48) and C3H10T1/2 cells (19). Further-
more, it has been shown that ABHA treatment of SCC25 cells
is associated with detachment and cell death (44). In the pres-
ent study, we found no evidence of apoptosis, by TUNEL assay,
in adherent HEKs and SCC25 cells following NaB, AAHA, or
SBHA treatment (data not shown). However, NaB, AAHA, and
SBHA treatment did cause a significant proportion of the ad-
herent SCC25 cells to lift off the culture dish. These data are
consistent with a non-apoptotic/necrotic mechanism of cell
death in SCC25 cells (data not shown). These data indicate that
the decrease in DNA synthesis observed in the adherent HEKs
following HDAC inhibitor treatment was not due to apoptosis
or cell death, whereas the G2/M phase accumulation, observed
in SCC25 cells, may be a prelude to detachment and cell death.
Histone Deacetylase Inhibitors Induce an Accumulation of
Acetylated Histone H4 in HEKs, HDFs, and SCC25 Cells—The
simplest explanation for the resistance of fibroblasts to the
histone deacetylase inhibitors is that the inhibitors are unable
to induce an accumulation of acetylated histones due to the
inactivity of these compounds in fibroblasts. We have shown
previously that accumulation of acetylated histones in kerati-
nocytes and SCC25 cells is transient and is maximal at 8 h in
response to NaB or TSA. Therefore, we treated HEKs, HDFs,
and SCC25 cells with the various HDAC inhibitors for 8 h and
then isolated the histone proteins from these cells. A Western
blot detecting acetylated histone H4 is shown in Fig. 2. These
data show that NaB, SBHA, and AAHA are able to induce an
hyperacetylation of histone H4 in all cell types (H4 acetylation
caused by AAHA is visible in HDFs with a longer gel exposure
time). These data also show that the inability of the HDAC
inhibitors to cause growth inhibition of HDFs is not due to an
inability to induce histone H4 acetylation (a similar result was
noted with H3 acetylation; data not shown). It is also of interest
to note that HMBA, R-PB, and S-PB did not induce an accu-
mulation of acetylated H4 and were unable to produce signifi-
cant growth arrest in any of the cells.
The inability to induce growth arrest in the HDFs, in re-
sponse to SBHA, was examined in more detail to determine
whether there were differences in the kinetics for the inhibition
of HDACs that may explain the inability of SBHA to cause
growth inhibition of HDFs (Fig. 3). Dose-response analysis for
the inhibition of growth (Fig. 3A) and the accumulation of
acetylated histone H4 (Fig. 3B) was examined in HEKs and
HDFs. SBHA induced growth inhibition in HEKs with an IC50
value of 11.7 6 8.5 mM (Fig. 3A). Similarly, SBHA induced an
accumulation of acetylated histone H4 in HEKs with an EC50
value 7.9 6 7.8 mM. In contrast, HDFs were resistant to the
growth inhibitory properties of SBHA (Fig. 3A) but accumu-
lated acetylated histone H4 with an EC50 value similar to that
for HEKs (1.0 6 1.8 mM). These data clearly show that, al-
though HDFs are resistant to the growth inhibitory properties
of SBHA, both HEKs and HDFs are sensitive to the HDAC
inhibitory action of SBHA.
An explanation for the resistance of HDFs to SBHA-medi-
ated growth inhibition could be due to the degradation/metab-
olism of SBHA by HDFs or HDF media. This possibility was
formally tested by taking media from HDFs treated with SBHA
for 24 h and placing it on SCC25 cells for an additional 24 h
(Fig. 3C). Media from HDFs treated with SBHA (300 mM) for
24 h was able to cause growth inhibition in SCC25 cells of
similar magnitude to that of SCC25 cells treated directly with
SBHA (Fig. 3C). This observation clearly indicates that SBHA
is not selectively inactivated by HDFs and suggests that an-
other explanation for the growth inhibitor resistance of HDFs
exists. This may include the possibility that 1) the HDAC
family member (e.g. HDACs 1–8; Refs. 34–52) responsible for
mediating growth inhibition, in response to SBHA, may be
absent or poorly expressed in fibroblasts compared with kera-
tinocytes or SCC cells; 2) the growth inhibitory action of the
HDAC inhibitors may be mediated by the hyperacetylation of
FIG. 1. Pocket protein (Rb, p107, p130) and p21 protein expres-
sion in HEKs, HDFs, and SCC25 cells in response to SBHA.
Keratinocytes (HEK), fibroblasts (HDF), and SCC25 cells (SCC) were
left untreated (2) or were treated with 100 mM SBHA for 24 h (1).
Twenty-five mg of cellular protein were electrophoresed, blotted, and
then probed for the expression of Rb, p21, p130, and p107. Hyperphos-
phorylated forms of Rb (RbPP) and p107 (P107PP) as well as hypophos-
phorylated forms of Rb and p107 are shown.
FIG. 2. Accumulation of acetylated histone H4 in response to
HDAC inhibitors. Histones were purified from cultured human epi-
dermal keratinocytes (HEK), human dermal fibroblasts (HDF), or
SCC25 cells (SCC25) following treatment with potential HDAC inhib-
itors for 8 h (lanes 2–7). Five mg of purified histone protein were then
run on a 15% SDS-PAGE gel, blotted, and probed with an antibody
specific for acetylated histone H4. NaB 5 3 mM; R-PB 5 6 mM; S-PB 5
6 mM; AAHA 5 3 mM; SBHA 5 100 mM; HMBA 5 1 mM.
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non-histone proteins; or 3) the HDAC complexes involved in
SBHA-induced growth inhibition may be cell type-specific or
gene-specific.
HEKs and HDFs Have a Different Complement of HDAC
mRNA Expression—The lack of an association between the
hyperacetylation of histones and the inhibition of growth of
HDFs, in response to HDAC inhibitors, may be attributable to
cell type-specific expression of different HDAC family mem-
bers. We therefore screened the HEKs, HDFs, and SCC25 cells
by Northern analysis to determine whether the growth inhib-
itory response to HDAC inhibitors was associated with the
expression of specific HDAC family members (HDACs 1–6; Fig.
4). There are currently eight reported HDAC family members
comprising type 1 HDACs (HDACs 1–3 and 8) and type 2
HDACs (HDACs 4–7); HDAC1 (34), HDAC2 (36), HDAC3 (37,
49), HDAC4, HDAC5, HDAC6 (35), HDAC7 (50, 51), and
HDAC8 (52). Analysis of HDACs 1–6 indicated that mRNA
expression for the type 1 HDACs 1 and 5 were similar between
untreated keratinocytes and fibroblasts when normalized for
GAPDH expression (Fig. 4). In contrast, expression of HDAC2
and HDAC6 was greater in untreated keratinocytes than in
fibroblasts. Furthermore, the expression of HDAC6 in HEKs
was restricted to one highly expressed transcript of ;6 kilobase
pairs, whereas both HDFs and SCC25 cells (data not shown)
expressed very little of this transcript but did express two
smaller transcripts at lower expression levels (Fig. 4). The
expression of HDAC4 was difficult to assess, due to its high
molecular mass (approximately 9 kilobase pairs; Ref. 35). How-
ever, keratinocytes expressed two large transcripts whereas
fibroblasts expressed two smaller transcripts (Fig. 4). As with
HDAC6, we did not determine whether the difference in tran-
scripts was due to alternate spliced variants, different pro-
moter usage, or different closely related gene transcripts. In-
terestingly, the expression of HDACs 1, 2, and 5 in HDFs
FIG. 3. Kinetics of growth suppression and histone H4 acety-
lation of HEKs and HDFs in response to varying concentrations
of SBHA. Proliferating keratinocytes (HEK) or dermal fibroblasts
(HDF) were treated with varying concentrations of SBHA. DNA syn-
thesis in response to a 24-h treatment with varying concentrations of
SBHA was then estimated by thymidine incorporation (A). For DNA
synthesis cells were incubated with 2.5 mCi of [3H] thymidine for 3 h,
followed by analysis of dpm of thymidine/mg of cellular protein. Data are
presented as mean 6 S.E. of triplicate determinations from two exper-
iments and expressed as a percentage of the value of the untreated cells.
The line represents the line of best fit determined by nonlinear regres-
sion analysis (HEK; l ) or linear regression analysis (HDF; E). B,
following an 8-h treatment of HEKs and HDFs with varying concentra-
tions of SBHA, histone proteins were purified and 5 mg were used in a
Western blot to determine histone H4 acetylation. Autoradiograms
were scanned by laser scanning densitometer and data fitted by non-
linear regression analysis. Data for keratinocytes (HEK; l ) and fibro-
blasts (HDF; E) represent mean 6 S.E. of at least four independent
experiments. Histone acetylation is presented as arbitrary units. C,
DNA synthesis was measured in untreated proliferating SCC25 cells
(PROL) or in SCC25 cells treated with 300 mM SBHA for 48 h (48 hr
SCC25). Alternatively, HDFs were treated with 300 mM SBHA for 24 h
and the media removed and placed on SCC25 cells for another 24 h (24
hr HDF/24 hr SCC25). Data are presented as mean 6 S.E. of triplicate
determinations.
FIG. 4. mRNA expression levels for HDACs 1–6 in HEKs and
HDFs. Keratinocytes (HEK) and fibroblasts (HDF) were left untreated
(2) or were treated with 100 mM SBHA for 24 h (1). Total RNA was then
isolated and enriched for poly(A)1 RNA. One microgram of poly(A)1
RNA was then electrophoresed, blotted, and probed with cDNA probes
specific for HDACs 1–6 or GAPDH (A). Autoradiograms were scanned
with a laser densitometer and imported into Adobe Photoshop. Quan-
titation of mRNA expression is presented (B). Data are normalized for
GAPDH expression.
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appeared to be induced following treatment of cells with 100 mM
SBHA for 24 h (Fig. 4). The data for HDAC mRNA expression
in SCC25 cells resembled that of the fibroblasts (data not
shown). Although similar amounts of poly(A)1 RNA were used
for HEKs and HDFs, the HDFs consistently showed lower
levels of GAPDH mRNA expression. This most likely reflects
differences in GAPDH mRNA expression between HEKs and
HDFs. Densitometric analysis in which normalization for
GAPDH expression is estimated is shown in Fig. 4B.
HDAC1, HDAC4, and HDAC6 Restores SBHA-induced
Growth Inhibition in HDFs—The data in Fig. 4A indicate that
there are some differences in the mRNA expression levels and
transcript species between HEKs and HDFs. This raises the
possibility that different HDAC family members contribute to
the difference in response between HEKs and HDFs. To test
this we transfected HDFs with expression plasmids for the
neomycin resistance gene (pSV2neo) and either pBJ5 (control
vector) or plasmids coding for HDAC1, HDAC4, HDAC5, or
HDAC6. Pooled colonies were enriched in media containing 500
mg/ml G418 and then treated with vehicle or 100 mM SBHA.
Fig. 5A shows that the selected HDFs express the relevant
FLAG-tagged HDAC with which they were transfected. Of the
selected cells, HDAC1 appeared to have the highest expression
followed by HDAC6 and then HDAC4 (Fig. 5A). HDAC5-trans-
fected cell lines could not be established and appeared to un-
dergo premature senescence (data not shown). Analysis of DNA
synthesis in the cell lines indicated that the control selected
cells were still resistant to the growth inhibitory properties of
SBHA whereas HDAC1-, HDAC4-, and HDAC6-expressing
cells had become profoundly sensitive to SBHA (Fig. 5B). Fur-
thermore, the DNA synthesis between the untreated cell lines
was similar, indicating that HDAC1, -4, and -6 expression did
not alter constitutive proliferation of the HDFs. It was inter-
esting to note that, although there was no difference in DNA
synthesis between the untreated control and HDAC1-,
HDAC4-, and HDAC6-expressing cells, there were some
marked differences in their cell cycle profile (Fig. 5C). For
instance, HDAC4-expressing cells have an increased percent-
age of cells in the G2/M phase (Fig. 5C). Thus, although our
data revealed little change in DNA synthesis in the HDAC-
expressing cells, there were profound changes in the distribu-
tion of HDAC4-expressing cells in the cell cycle, suggesting
that transit through the cell cycle phases can be altered by
overexpressing HDAC4. Furthermore, these data would sug-
gest that the ability to induce growth inhibition in response to
SBHA is not restricted to a particular HDAC but is a property
of type 1 (HDAC1) and type 2 HDACs (HDACs 4 and 6).
Recent studies have shown that non-histone proteins are the
target for acetylation/deacetylation (30). We considered the
possibility that the growth inhibition of HEKs and SCC25 cells,
in response to SBHA, may be associated with a hyperacetyla-
tion of proteins that were not hyperacetylated in HDFs (Fig. 6).
Western blot analysis, using a generic anti-acetyllysine anti-
body, revealed four protein bands in HEKs and SCC25 cells
that were hyperacetylated in response to SBHA and were not
hyperacetylated in HDFs (Fig. 6). However, a similar analysis
of HDFs overexpressing HDAC1, HDAC4, or HDAC 6 did not
show any corresponding hyperacetylation of proteins, in re-
sponse to SBHA, that were similar to HEKs (data not shown).
These data indicate that, although there are increases in pro-
teins in HEKs and SCC25 cells, that are immunoreactive to an
anti-acetyllysine antibody, following SBHA treatment, these
same protein bands were not increased in HDFs or in HDFs
overexpressing HDAC1, HDAC4, or HDAC6.
DISCUSSION
In the present study we have examined the ability of various
HDAC inhibitors to induce histone acetylation and growth
inhibition in normal keratinocytes, transformed keratinocytes,
and normal fibroblasts. Our results indicate that, although all
three cell types were similarly responsive to the HDAC inhib-
itors, with respect to the accumulation of acetylated histone
FIG. 5. Overexpression of HDAC1,
HDAC4, and HDAC6 causes growth
inhibition of fibroblasts in response
to SBHA. HDFs were transfected with
expression plasmids for HDAC1, HDAC4,
HDAC6, or control plasmid (pBJ5). Cells
were selected in G418 and then pooled
clones analyzed for expression of the
FLAG-tagged HDAC protein in untreated
(2) or SBHA-treated (1, 100 mM) cells (A)
or growth inhibition in response to 24-h
treatment with SBHA (100 mM) (B). Data
represent the mean 6 S.E. of six determi-
nations and are presented as dpm incor-
porated [3H]thymidine/mg of cellular pro-
tein. C, constitutive cell cycle profile of
the untreated cell lines expressing the
HDACs.
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H4, they were dissimilar in their ability to respond to the
growth inhibitory properties of the HDAC inhibitors. Overall,
our data provide evidence that the action of specific HDACs
and HDAC inhibitors is complex and may involve mechanisms
in addition to histone acetylation.
Histone H4 Acetylation Is Not Sufficient to Cause HDAC
Inhibitor-mediated Growth Inhibition—There is a growing
body of evidence suggesting that HDAC inhibitor-induced
growth inhibition may be independent of the effects of the
HDAC inhibitors on global histone acetylation status (30).
Clearly, our data with HDFs indicate that increases in histone
H4 acetylation status can occur in response to HDAC inhibitors
in the absence of growth inhibition. Further support for the
discordance between HDAC inhibitor-induced histone hyper-
acetylation and growth inhibition can be seen in cells in which
both growth inhibition and histone hyperacetylation occur. For
instance, the accumulation of acetylated histones, induced by
HDAC inhibitors, in keratinocytes, transformed keratinocytes
(21), and colon carcinoma cells (53) is transient. Moreover, in
keratinocytes, the time at which growth inhibition occurs is not
associated with hyperacetylation of histone H4 (21). Although
it remains a formal possibility that the transient hyperacety-
lation of histones that precedes growth inhibition is sufficient
to initiate growth inhibition, it is unlikely because HDAC in-
hibitor-induced growth suppression requires the continued
presence of inhibitor at a time at which histone H4 acetylation
has returned to basal levels (21). A similar finding for HT-29
cells has also been reported (15). These data indicate that the
temporal events associated with histone hyperacetylation and
growth inhibition, in response to HDAC inhibitors, are not
consistent with histone acetylation being the sole mediator of
growth inhibition. Furthermore, we show that SBHA-induced
H4 acetylation in normal fibroblasts is maximal at a dose that
is not associated with growth inhibition. A similar lack of
correlation between histone acetylation and growth inhibition
has been reported previously for fibroblasts (18, 20), murine
erythroleukemia cells (22), and MCF-7 cells (54) treated with
HDAC inhibitors. Thus, HDAC-mediated growth inhibition in
HDFs and HEKs has been shown to be temporally and kinet-
ically independent of histone acetylation status.
Although it may be argued that the genes responsible for
inhibiting growth in response to HDAC inhibitors are
“switched off/silenced” in fibroblasts, this would seem unlikely
since the overexpression of HDACs 1, 4, and 6 in fibroblasts is
able to render the cells sensitive to growth inhibition by SBHA.
This is also supported by the lack of further acetylation in the
presence of excess HDAC inhibitor in HDFs. This would argue
that all histone H4 that could be hyperacetylated has been in
the HDFs. Finally, the ability of overexpressed HDACs 1, 4, or
6 to render the HDFs sensitive to growth inhibition by SBHA
indicates that the ability to induce growth suppression is not
restricted to specific HDACs or HDAC types.
If histone hyperacetylation is not sufficient to cause HDAC
inhibitor-induced growth arrest, what are the targets of HDAC
inhibitor action that contribute to growth inhibition? One pos-
sibility is that HDAC inhibitors have non-histone targets such
as structural proteins (30), transcription factors (26–28, 55,
56), or cell cycle regulators (57). Attempts to identify possible
non-histone protein targets by comparing acetyllysine profiles
for HEKs, HDFs, and SCC25 cells, using a generic anti-acetyl-
lysine antibody, indicated that there are non-histone proteins
that are hyperacetylated in response to SBHA in HEKs and
SCC25 cells that are not hyperacetylated in HDFs. Although
these data provide tantalizing evidence of potential HDAC
targets, it will require more rigorous analysis to determine
their role, if any, in mediating SBHA-induced growth inhibition.
Despite this, our data clearly show that the regulation of any
alternative regulatory pathway(s), mediating HDAC inhibitor
affects, clearly requires HDACs since overexpressed HDACs 1, 4,
and 6 reinstate growth inhibitor sensitivity to HDFs. Although
these observations do not preclude a role for histone acetylation
in HDAC-mediated growth inhibition, they do show they are not
sufficient to induce growth inhibition in HDFs.
Anti-proliferative Effects of HDAC Inhibitors Is Mechanisti-
cally Different between Normal Keratinocytes and Transformed
Keratinocytes—The present study has demonstrated that the
mechanism by which HDAC inhibitors induce growth inhibi-
tion is cell type-specific and possibly transformation-specific.
For instance, SBHA treatment caused an accumulation of nor-
mal keratinocytes in the G0/G1 phase of the cell cycle, which
was associated with an induction of the cyclin-dependent ki-
nase inhibitor, p21 and an accumulation of hypophosphory-
lated pocket proteins pRb and p107. In transformed keratino-
cytes (SCC25 cells), SBHA treatment caused an accumulation
of cells in the G2/M phase and non-apoptotic cell death, which
was also associated with an induction of p21 but no accumula-
tion of hypophosphorylated pocket proteins pRb or p107. In
contrast, human dermal fibroblasts were not growth-inhibited
by SBHA yet still induced an increase in p21 expression. The
induction of p21 by SBHA in HDFs was unexpected since it was
not associated with reduced DNA synthesis. A similar finding
has been reported by others (14). Furthermore, the p21 induced
in HDFs, in response to SBHA, appeared to be inactive since it
was not associated with a cell cycle block or an accumulation of
hypophosphorylated pocket proteins. This suggests that p21
may not be a universal marker of HDAC inhibitor-mediated
FIG. 6. SBHA causes increase in anti-acetyllysine immunore-
active bands in HEKs and SCC25 cells but not HDFs. Keratino-
cytes (HEK), fibroblasts (HDF), and SCC25 cells (SCC) were left un-
treated (2) or were treated with 100 mM SBHA for 8 h (1). Twenty-five
mg of cellular protein was extracted, electrophoresed, blotted, and then
probed for the expression of acetylated lysine. Acetylation status of
histone H4 is shown at the top to verify the efficacy of SBHA. Arrows
indicate immunoreactive bands that are induced in HEKs and SCC25
cells but not in HDFs.
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actions and is consistent with the proposition that the response
to HDAC inhibitors is cell type-specific (58). In this respect, it
is important to note that epithelial cells are capable of under-
going irreversible growth arrest and terminal differentiation
whereas fibroblasts generally undergo a reversible growth ar-
rest and are not thought to undergo terminal differentiation.
Given the very different biological fates of epithelial versus
mesenchymal cells, it is not unexpected that they may respond
to similar stimuli in different ways.
The cell type specificity of action of the HDAC inhibitors on
the cell cycle may help to explain the seemingly paradoxical
role of HDACs and HDAC inhibitors in regulating the p21/Rb/
E2F axis. For instance, p21 is known to inhibit phosphorylation
of Rb, suppress E2F activity, and inhibit proliferation. HDACs
repress p21 transcription (45–47, 59), and release of this re-
pression by HDAC inhibitors leads to induction of p21 and
growth inhibition (4, 15). Conversely, HDAC inhibitors have
been reported to relieve Rb-mediated E2F inhibition, resulting
in E2F activation (23–25) and hence proliferation. Clearly,
these effects of HDAC inhibitors upon p21 transcription and Rb
activity oppose one another. This suggests that the biological
consequences of HDAC inhibitor treatment may in fact repre-
sent the sum of these two, or more, opposing actions, which in
turn may explain the differing biological outcomes for HEKs,
HDFs, and SCC25 cells treated with HDAC inhibitors. For
instance SBHA-mediated p21 induction in HEKs is associated
with pocket protein hypophosphorylation and growth arrest,
whereas in SCC25 cells, which have defective Rb/E2F regula-
tion (31, 38), p21 induction is associated with an accumulation
in G2/M. In contrast, p21 induction in HDFs is not associated
with hypophosphorylation of pocket proteins or cell cycle block,
suggesting that a higher level of proliferative regulation
predominates.
Possible Mechanisms for HDAC Inhibitor Action in Normal
Keratinocytes, Fibroblasts, and Transformed Keratinocytes—
The lack of an effect on constitutive DNA synthesis by overex-
pressed HDACs suggests that in normal HDFs the activity of
HDACs may be subordinate to preexisting pathways control-
ling proliferation. Although the identity of such pathways is
unknown, it is possible to speculate on the nature of such
pathways. Thus, one could speculate on the existence of a
regulatory framework in normal fibroblasts (or other cells) that
is controlled by the location or interaction of HDACs with other
regulatory proteins such that HDAC inhibitors have little ef-
fect on proliferation. When these processes are overwhelmed
through the overexpression of HDACs, the normal regulatory
interactions are saturated leading to the availability of HDACs
to interfere with cell cycle progression. This notion gains fur-
ther support from the observation that overexpression of
HDAC4 is able to disrupt the constitutive cell cycle phases in
fibroblasts, resulting in an equivalent fraction of cells existing
in the G0/G1 phase as in the G2/M phase. This proposition also
is supported by the growth inhibition in HDFs overexpressing
HDACs 1, 4, and 6 following treatment with SBHA. Moreover,
recent reports suggest that the activity and subcellular local-
ization of HDACs may be critical events in regulating differen-
tiation control (60, 61).
The profound growth arrest of fibroblasts overexpressing
HDACs 1, 4, and 6 in response to SBHA is consistent with a
process in which proliferation control by HDACs and HDAC
inhibitors in normal HDFs is selectively suppressed by homeo-
static growth pathways. This implies that certain cells may
have an intrinsic resistance to HDAC inhibitor-induced growth
inhibition dependent upon the relative activity of these regu-
latory pathways. Such a proposal is not unprecedented since
the discovery of interactions of HDACs with key cellular regu-
lators (58, 60–62) associated with growth and differentiation
control, which indicate that the available “active” HDACs may
be regulated by their interaction with, or sequestration by,
other intracellular effector molecules (60, 62). For instance,
HDACs are known to interact with E2F1 (26), p53 (27, 28),
14-3-3 (58, 62), MEF2A (55), Sp1 (56), ERK 1/2 (61), or Hus1/
Rad9 (57). These disparate partner proteins reflect the growing
complexity of our understanding of how HDACs may work and
how HDAC-dependent affects may be determined by non-his-
tone protein interactions. These data also establish that his-
tone acetylation alone may not be sufficient to mediate HDAC
inhibitor-induced actions.
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